Effects of skyrin, a receptor-selective glucagon antagonist, in rat and human hepatocytesPARKER, Janice C; MCPHERSON, R. Kirk; DEKKER, Koen A et al.Diabetes (New York, NY). 2000, Vol 49, Num 12, pp 2079-2086, issn 0012-1797Article

(3,3-Difluoro-pyrrolidin-1-yl)-[(2S,4S)-4-(4-pyrimidin-2-yl-piperazin-1-yl)-pyrrolidin-2-yl]-methanone : A potent, selective, orally active dipeptidyl peptidase IV inhibitorAMMIRATI, Mark J; ANDREWS, Kim M; PARKER, Janice C et al.Bioorganic & medicinal chemistry letters (Print). 2009, Vol 19, Num 7, pp 1991-1995, issn 0960-894X, 5 p.Article

Endogenous effectors of human liver glycogen phosphorylase modulate effects of indole-site inhibitorsERCAN-FANG, Nacide; TAYLOR, Miriam R; TREADWAY, Judith L et al.American journal of physiology. Endocrinology and metabolism. 2005, Vol 52, Num 3, pp E366-E372, issn 0193-1849Article

3-(2-Carboxyethyl)-4,6-dichloro-1H-indole-2-carboxylic acid: An allosteric inhibitor of fructose-1,6-bisphosphatase at the AMP siteWRIGHT, Stephen W; CARLO, Anthony A; WANG, Ing-Kae et al.Bioorganic & medicinal chemistry letters (Print). 2003, Vol 13, Num 12, pp 2055-2058, issn 0960-894X, 4 p.Article

Three-dimensional quantitative structure-activity relationship analysis of human CYP51 inhibitorsEKINS, Sean; MANKOWSKI, Dayna C; HOOVER, Dennis J et al.Drug metabolism and disposition. 2007, Vol 35, Num 3, pp 493-500, issn 0090-9556, 8 p.Article

(3R,4S)-4-(2,4,5-trifluorophenyl)-pyrrolidin-3-ylamine inhibitors of dipeptidyl peptidase IV: Synthesis, in vitro, in vivo, and X-ray crystallographic characterizationWRIGHT, Stephen W; AMMIRATI, Mark J; OLSON, Thanh V et al.Bioorganic & medicinal chemistry letters (Print). 2007, Vol 17, Num 20, pp 5638-5642, issn 0960-894X, 5 p.Article

cis-2,5-dicyanopyrrolidine inhibitors of dipeptidyl peptidase. IV: Synthesis and in vitro, in vivo, and X-ray crystallographic characterizationWRIGHT, Stephen W; AMMIRATI, Mark J; PARKER, Janice C et al.Journal of medicinal chemistry (Print). 2006, Vol 49, Num 11, pp 3068-3076, issn 0022-2623, 9 p.Article

Allosteric inhibition of fructose-1,6-bisphosphatase by anilinoquinazolinesWRIGHT, Stephen W; HAGEMAN, David L; MCCLURE, Lester D et al.Bioorganic & medicinal chemistry letters (Print). 2001, Vol 11, Num 1, pp 17-21, issn 0960-894XArticle

1-((3S,4S)-4-Amino-1-(4-substituted-1,3,5-triazin-2-yl) pyrrolidin-3-yl)-5, 5-difluoropiperidin-2-one inhibitors of DPP-4 for the treatment of type 2 diabetesANDREWS, Kim M; BEEBE, David A; PIOTROWSKI, David W et al.Bioorganic & medicinal chemistry letters (Print). 2011, Vol 21, Num 6, pp 1810-1814, issn 0960-894X, 5 p.Article

Defective Glycogenesis Contributes Toward the Inability to Suppress Hepatic Glucose Production in Response to Hyperglycemia and Hyperinsulinemia in Zucker Diabetic Fatty RatsTORRES, Tracy P; FUJIMOTO, Yuka; DONAHUE, E. P et al.Diabetes (New York, NY). 2011, Vol 60, Num 9, pp 2225-2233, issn 0012-1797, 9 p.Article

The sulfonylurea glipizide does not inhibit ischemic preconditioning in anesthetized rabbitsFLYNN, David M; SMITH, Andrew H; KNIGHT, Delvin R et al.Cardiovascular drugs and therapy. 2005, Vol 19, Num 5, pp 337-346, issn 0920-3206, 10 p.Article

Cardioprotective effects of ingliforib, a novel glycogen phosphorylase inhibitorTRACEY, W. Ross; TREADWAY, Judith L; MUTCHLER, Alison K et al.American journal of physiology. Heart and circulatory physiology. 2004, Vol 55, Num 3, pp H1177-H1184, issn 0363-6135Article

Anilinoquinazoline inhibitors of fructose 1,6-bisphosphatase bind at a novel allosteric site: Synthesis, in vitro characterization, and X-ray crystallographyWRIGHT, Stephen W; CARLO, Anthony A; NESTOR, Nestor B et al.Journal of medicinal chemistry (Print). 2002, Vol 45, Num 18, pp 3865-3877, issn 0022-2623Article